跳至主要内容
临床试验/NCT00775866
NCT00775866已完成不适用

MRI - Guided Biopsy for Suspicion of Locally Recurrent Prostate Cancer After External Beam Radiotherapy

University Health Network, Toronto2 个研究点 分布在 1 个国家目标入组 82 人开始时间: 2006年10月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
82
试验地点
2
主要终点
The primary endpoint is a preliminary estimate of the diagnostic accuracy of MRI in identifying sites of recurrent tumor after radiotherapy for prostate cancer.

研究概览

简要总结

In this study we will test a new procedure to guide needle biopsies into the prostate gland based on MRI. This study will be conducted in patients who may have recurrence of their cancer in the prostate gland after radiation therapy in order to map out the location of the recurrence. Using this technique, we will be able to measure the accuracy of MR images in identifying the site of tumour recurrence.

详细描述

This study involves the technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table. We primarily hypothesize that the integration of diagnostic and interventional MRI enables needle biopsy targeting to foci of tumor recurrence after radiotherapy, and will enable a determination of the diagnostic accuracy of MRI in mapping sub-sites of tumor recurrence after radiotherapy. RELEVANCE TO PUBLIC HEALTH: Patients with recurrence of their prostate cancer after radiotherapy currently face difficult choices. Standard second line treatments target the entire prostate gland and are associated many side effects. This study will directly improve the detection, spatial delineation, and characterization of prostate cancer persistence after radiotherapy. If anatomic patterns of disease persistence are found across patients, radiation delivery techniques will be suitably modified, which may translate to improved cure rates. Importantly, this study will establish a procedural platform for MRI-guidance of minimally invasive local salvage therapies. By precisely focusing salvage therapy to sites of tumor persistence within the prostate gland, side effects may be reduced in the future.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Biochemical failure > 18 months after definitive external beam radiotherapy (ASTRO definition - revised version 2006: rise by 2 ng/mL or more above the nadir PSA)
  • PSA <20 prior to initial course of external beam radiotherapy
  • PSADT >3 months at failure
  • Age ≥ 18 years
  • ECOG performance status 0 or 1 with >10 year life expectancy
  • Fit for local anaesthesia
  • Informed consent:

排除标准

  • Contraindications to MRI
  • Severe claustrophobia
  • Bleeding diathesis and anti-coagulative therapy that cannot be temporarily ceased precluding brachytherapy
  • Previous brachytherapy
  • Active hormonal therapy
  • Radiologic evidence of LN or distant metastases
  • Other urinary or medical conditions deemed by the PI or associates to make the patient ineligible for MRI-guided prostate biopsy.
  • Contraindications to endorectal coil, surgically absent rectum, severe hemorrhoids or previous colorectal surgery
  • Contraindications to conscious sedation
  • Contraindication to IV Gadolinium administration
  • latex allergy

研究组 & 干预措施

MRI guided prostate biopsy

Experimental

干预措施: MRI-Guided Biopsy (Procedure)

结局指标

主要结局

The primary endpoint is a preliminary estimate of the diagnostic accuracy of MRI in identifying sites of recurrent tumor after radiotherapy for prostate cancer.

时间窗: at the end of the evaluation phase

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验